Thank you for subscribing to our newsletter.

Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.

BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.

Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.

BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.

Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.

BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.

As VP of AI, Dr Nicola Richmond will be responsible for spearheading BenevolentAI’s AI strategy and working to ensure the Company maintains its leading position in AI-enabled drug discovery.

BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.

BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.

AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.